References
- SharmaSBGargSSmall dense LDL: risk factor for coronary artery disease (CAD) and its therapeutic modulationIndian J Biochem Biophys201249277 8522650003
- TaylorFCHuffmanMEbrahimSStatin therapy for primary prevention of cardiovascular diseaseJAMA2013310222451 245224276813
- RosenbaumDDallongevilleJSabouretPBruckertEDiscontinuation of statin therapy due to muscular side effects: a survey in real lifeNutr Metab Cardiovasc Dis2013239871 87522748604
- AllaVMAgrawalVDeNazarethAMohiuddinSRavillaSRendellMA reappraisal of the risks and benefits of treating to target with cholesterol lowering drugsDrugs201373101025 105423754124
- CatapanoALFarnierMFoodyJMCombination therapy in dyslipidemia: where are we now?Atherosclerosis20142371319 33525299967
- YinJXingHYeJEfficacy of berberine in patients with type 2 diabetes mellitusMetabolism2008575712 71718442638
- ZhangHWeiJXueRBerberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expressionMetabolism2010592285 29219800084
- KongWWeiJAbidiPBerberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statinsNat Med200410121344 135115531889
- ChenWMiaoYQFanDJBioavailability study of berberine and the enhancing effects of TPGS on intestinal absorption in ratsAAPS PharmSciTech2011122705 71121637946
- PanGYWangGJLiuXDFawcettJPXieYYThe involvement of P-glycoprotein in berberine absorptionPharmacol Toxicol2002914193 19712530470
- TsaiPLTsaiTHHepatobiliary excretion of berberineDrug Metab Dispos2004324405 41215039293
- ChaeHWKimIWJinHEKimDDChungSJShimCKEffect of ion-pair formation with bile salts on the in vitro cellular transport of berberineArch Pharm Res2008311103 11018277615
- ShanYQRenGWangYXBerberine analogue IMB-Y53 improves glucose-lowering efficacy by averting cellular efflux especially P-glycoprotein effluxMetabolism2013623446 45623079743
- ZhouSLimLYChowbayBHerbal modulation of P-glycoproteinDrug Metab Rev200436157 10415072439
- Di PierroFVillanovaNAgostiniFMarzocchiRSoveriniVMarchesiniGPilot study on the additive effects of berberine and oral type 2 diabetes agents for patients with suboptimal glycemic controlDiabetes Metab Syndr Obes20125213 21722924000
- DerosaGBonaventuraABianchiLBerberis aristata/Silybum marianum fixed combination on lipid profile and insulin secretion in dyslipidemic patientsExpert Opin Biol Ther201313111495 150623971720
- DerosaGBonaventuraABianchiLEffects of Berberis aristata/Silybum marianum association on metabolic parameters and adipocytokines in overweight dyslipidemic patientsJ Biol Regul Homeost Agents2013273717 72824152839
- Di PierroFPutignanoPVillanovaNMontesiLMoscatielloSMarchesiniGPreliminary study about the possible glycemic clinical advantage in using a fixed combination of Berberis aristata and Silybum marianum standardized extracts versus only Berberis aristata in patients with type 2 diabetesClin Pharmacol20135167 17424277991
- World Medical AssociationWorld Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjectsJ Postgrad Med2002483206 20812432198
- CameronJRanheimTKulsethMALerenTPBergeKEBerberine decreases PCSK9 expression in HepG2 cellsAtherosclerosis20082012266 27318355829
- DongHZhaoYZhaoLLuFThe effects of berberine on blood lipids: a systemic review and meta-analysis of randomized controlled trialsPlanta Med2013796437 44623512497
- ShanYQZhuYPPangJTetrandrine potentiates the hypoglycemic efficacy of berberine by inhibiting P-glycoprotein functionBiol Pharm Bull201336101562 156923924821